Newborn Screening Market Marketing Channel, Future Trends, Manufacturers GE Life Sciences, Masimo, Natus Medical, PerkinElmer, and ZenTech S.A

Newborn screening describes various tests that are performed during first few hours or days of an infant’s life. These tests have the potential for preventing severe health problems, including death. Newborn screening has evolved from a simple urine or blood screening test to a more comprehensive and complex screening system capable of detecting over 50 different conditions. Newborn screening tests measure a number of markers in infant’s blood that can be either decreased or increased if an infant has certain diseases. Currently, conditions such as cystic fibrosis (CF), congenital hypothyroidism, phenylketonuria (PKU), and around 22 other metabolic conditions that affect protein or fat metabolism can be diagnosed through newborn screening tests.

The global newborn screening market size was valued at US$ 561.5 million in 2018, and is expected to witness a CAGR of 12.4% over the forecast period (2018 – 2026).

Increasing number of newborn screenings, owing to rising awareness among parents and governments is expected to drive the newborn screening market growth. According to the Centers for Disease Control and Prevention (CDC) 2017, four million infants in the U.S. are routinely screened, using a few drops of blood from their heel, for certain endocrine, genetic, and metabolic disorders. The infants are also tested for hearing loss and Critical Congenital Heart Defects (CCHDs) prior to discharge from a hospital or birth center. Furthermore, increasing incidence of hospital acquired diseases create an acute need for newborn screening. For instance, according to the Center for Disease Control and Prevention (CDC), in 2011, around one in every 25 infants was infected with at least one hospital acquired infections.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2192

Government initiatives to support screening of newborns is also a major factor driving the newborn screening market. For instance, CDC is working to harness the latest advances in science and technology so that more disorders can be identified accurately and treated quickly. In 2005, CDC established the Newborn Screening Translation Research Initiative (NSTRI) with the CDC Foundation. NSTRI works with corporate, academic, and foundation partners to assure the quality of research methods during both pilot studies and routine screening. However, lack of skilled professional, proper infrastructure and parent awareness in emerging regions are some of the major factors confining the newborn screening market. Moreover, the natural history for several diseases has not been well characterized and the effective follow-up and treatment may not be known. Excessive false-positive results of screening tests may produce additional costs to the healthcare system. However, improvements in newborn screening tests is expected to reduce number of false positives.

Newborn screening programs test infants for disorders that are often not apparent at birth. Such disorders may be infectious, inherited, or caused by a medical problem in the mother. Early detection and treatment of some disorders can help prevent severe intellectual disability, health problems, growth problems, or even sudden infant death.

Furthermore, early disease diagnosis can reduce treatment cost. According to the Association of Public Health Laboratories 2012 report, the Medicaid cost of treating an infant with Severe Combined Immunodeficiency (SCID), which is fatal in the first two years of life without immune reconstitution, can reach US$ 2 million. However, if infants are diagnosed early, before developing life-threatening infections, from exposure to live childhood vaccines or common germs, they can be cured with a bone marrow transplant. The cost of the transplant is approximately US $100,000 when performed within the first 3.5 months of life.

On the basis of region, the global newborn screening market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. By 2026, North America and Europe are expected to generate major revenue share in the global newborn screening market, owing to the presence of a better reimbursement structure, development of well-equipped healthcare infrastructure, and availability of trained medical professionals. According to the U.S. government, for the 2018 fiscal year, the Newborn Screening Quality Assurance Program at the CDC is funded at US$ 8.4 million and the Heritable Disorders program at Health Resources and Services Administration (HRSA) is funded at $13.88 million. The most common newborn screening tests in the U.S. include, hypothyrodism, galactosemia, PKU (phenylketonuria), and sickle cell disease. Increasing government funding in Europe for NBS within a national health service or a statutory health insurance, is expected to drive newborn screening market growth in Europe.

Key players operating in the global newborn screening market include, Agilent Technologies, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., and ZenTech S.A.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2192

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.